KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Treasury Shares (2016 - 2025)

AbbVie (ABBV) has disclosed Treasury Shares for 13 consecutive years, with $9.1 billion as the latest value for Q3 2025.

  • On a quarterly basis, Treasury Shares changed N/A to $9.1 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $9.1 billion, a N/A change, with the full-year FY2024 number at $8.2 billion, up 25.53% from a year prior.
  • Treasury Shares was $70.8 million for Q4 2025 at AbbVie, roughly flat from $70.8 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $70.8 million in Q2 2025 to a low of $5.0 million in Q1 2021.
  • A 5-year average of $30.2 million and a median of $12.0 million in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: soared 46.17% in 2022, then rose 25.53% in 2024.
  • AbbVie's Treasury Shares stood at $3.1 billion in 2021, then skyrocketed by 46.17% to $4.6 billion in 2022, then soared by 42.21% to $6.5 billion in 2023, then rose by 25.53% to $8.2 billion in 2024, then grew by 11.49% to $9.1 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Treasury Shares are $9.1 billion (Q3 2025), $9.1 billion (Q2 2025), and $8.2 billion (Q4 2024).